TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06786624: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Sponsor: Neurocrine Biosciences · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 200 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$3,111,504

Rescue Site Savings

+$2,074,336

Unlock Full NCT06786624 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06786624 Rescue Dossier →